Antibiotic Prophylaxis in Rhinoplasty
Launched by STANFORD UNIVERSITY · Dec 9, 2019
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The study will consist of 2 treatment arms:
Treatment arm A: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.
Treatment arm B: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg every 4 hours or "clindamycin" 150mg every 6 hours, for a duration of three days.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (aged 18years and older)
- Exclusion Criteria:
- • Prior rhinoplasty
- • Any exogenous (non-nasal) grafts/implants
- • Immune deficiency (DM, meds, other)
- • History of radiotherapy to nose
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Trial Officials
Sam P Most, MD
Principal Investigator
Stanford Facial Plastic and Reconstructive Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials